Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …

Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …

Tirzepatide is a new drug targeting glucagon-like peptide 1 (GLP1) and gastric inhibitory
polypeptide (GIP) receptors. This drug has demonstrated great potential in improving the …

Aims Though statin therapy is known to slow coronary atherosclerosis progression and
reduce cardiovascular (CV) events, significant CV risk still remains. In the REDUCE-IT study …

Owing to their potent glucose-lowering efficacy and substantial weight loss effects, glucagon-
like peptide-1 receptor agonists (GLP-1 RAs) are now considered part of the frontline …

Atherosclerosis is a very common macrovascular complication in type 2 diabetes mellitus,
and cardiovascular disease is the primary cause of death in diabetes patients. Sodium …

Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon‐like peptide 1
receptor agonists (GLP‐1 RAs) are incretin‐based agents that lower both blood sugar levels …

Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) lower plasma glucose
through effects on insulin and glucagon secretion and by decelerating gastric emptying. GLP …

Abstract Introduction Type 2 diabetes (T2D) management has reached a point where not
only optimal glycaemic control is necessary, but also additional interventions with proven …